Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Living Cell Technologies ( (AU:1AI) ) has shared an announcement.
Algorae Pharmaceuticals has announced significant advancements in its operations, including a strategic partnership with the Peter MacCallum Cancer Centre to validate AI-driven drug synergy predictions for four major cancer types. The company is also progressing with the development of AlgoraeOS Version 2.0, which promises enhanced predictive accuracy and scalability, and is advancing its therapeutic pipeline with promising preclinical results for its lead drug candidates, AI-116 and AI-168.
More about Living Cell Technologies
Algorae Pharmaceuticals Ltd is an AI-enabled pharmaceutical development company focused on drug discovery and validation. The company specializes in leveraging artificial intelligence to enhance drug synergy screening and therapeutic pipeline development, with a market focus on oncology and other critical health areas.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$10.12M
Find detailed analytics on 1AI stock on TipRanks’ Stock Analysis page.